Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis b...
Saved in:
| Published in | Respiratory research Vol. 24; no. 1; p. 133 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
17.05.2023
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction.
The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib's effect and identify potential correlated effects.
NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG.
These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients.
The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. |
|---|---|
| AbstractList | Abstract Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. Methods The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib’s effect and identify potential correlated effects. Results NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. Conclusions These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. Trial registration: The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. Abstract Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. Methods The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib’s effect and identify potential correlated effects. Results NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. Conclusions These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. Trial registration: The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. Methods The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib's effect and identify potential correlated effects. Results NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. Conclusions These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. Trial registration: The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. Keywords: Non-cystic fibrosis bronchiectasis, Brensocatib, Dipeptidyl peptidase-1 inhibitor, Neutrophil serine protease, Sputum biomarkers, Neutrophil elastase, Proteinase 3, Cathepsin G BACKGROUNDBrensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. METHODSThe 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib's effect and identify potential correlated effects. RESULTSNE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. CONCLUSIONSThese results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. TRIAL REGISTRATIONThe study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib's effect and identify potential correlated effects. NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. BackgroundBrensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction.MethodsThe 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib’s effect and identify potential correlated effects.ResultsNE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG.ConclusionsThese results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients.Trial registration: The study was approved by the corresponding ethical review boards of all participating centers. The trial was approved by the Food and Drug Administration and registered at clinicaltrials.gov (NCT03218917) on July 17, 2017 and approved by the European Medicines Agency and registered at the European Union Clinical trials Register (EudraCT No. 2017-002533-32). An independent, external data and safety monitoring committee (comprising physicians with pulmonary expertise, a statistician experienced in the evaluation of clinical safety, and experts in periodontal disease and dermatology) reviewed all adverse events. Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs) including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG). In chronic inflammatory lung diseases such as non-cystic fibrosis bronchiectasis (NCFBE), neutrophils accumulate in the airways resulting in excess active NSPs that cause damaging inflammation and lung destruction. The 24-week WILLOW trial (NCT03218917) was a randomized, double-blind, placebo-controlled, parallel-group trial in patients with NCFBE conducted at 116 sites across 14 countries. In this trial, treatment with brensocatib was associated with improvements in clinical outcomes including time to first exacerbation, reduction in exacerbation frequency and a reduction in NE activity in sputum. An exploratory analysis of NE activity in white blood cell (WBC) extracts and NE, PR3 and CatG activity in sputum was conducted to further characterize brensocatib's effect and identify potential correlated effects. NE, PR3 and CatG activities were reduced in sputum and NE activity was reduced in WBC extracts in a dose-dependent manner after four weeks of brensocatib treatment, with a return to baseline four weeks after the end of treatment. Brensocatib produced the greatest reduction in the sputum activity of CatG, followed by NE and then PR3. Positive correlations among the sputum NSPs were observed both at baseline and in response to treatment, with the strongest correlation among the sputum NSPs for NE and CatG. These results suggest a broad anti-inflammatory effect of brensocatib underlying its clinical efficacy observed in NCFBE patients. |
| ArticleNumber | 133 |
| Audience | Academic |
| Author | Lasala, Daniel Zhang, Jimin Perkins, Walter R Cipolla, David Fernandez, Carlos Basso, Jessica Chalmers, James D Sullivan, Eugene J Mange, Kevin C Korkmaz, Brice Teper, Ariel |
| Author_xml | – sequence: 1 givenname: David surname: Cipolla fullname: Cipolla, David email: david.cipolla@insmed.com organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA. david.cipolla@insmed.com – sequence: 2 givenname: Jimin surname: Zhang fullname: Zhang, Jimin organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 3 givenname: Brice surname: Korkmaz fullname: Korkmaz, Brice organization: INSERM UMR-1100, "Research Center for Respiratory Diseases" and University of Tours, Tours, France – sequence: 4 givenname: James D surname: Chalmers fullname: Chalmers, James D organization: Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK – sequence: 5 givenname: Jessica surname: Basso fullname: Basso, Jessica organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 6 givenname: Daniel surname: Lasala fullname: Lasala, Daniel organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 7 givenname: Carlos surname: Fernandez fullname: Fernandez, Carlos organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 8 givenname: Ariel surname: Teper fullname: Teper, Ariel organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 9 givenname: Kevin C surname: Mange fullname: Mange, Kevin C organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 10 givenname: Walter R surname: Perkins fullname: Perkins, Walter R organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA – sequence: 11 givenname: Eugene J surname: Sullivan fullname: Sullivan, Eugene J organization: Insmed Incorporated, 700 US Highway 202/206, Bridgewater, NJ, 08807, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37198686$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1r3DAQhk1JaT7aP9BDEfTSi1PLlrVyLyWkXwsLubSkNyHLo_UsXsmV5JTNn-pfrHY3CbulCCFp5p1HzPCeZyfWWciy17S4pFTw94GWTUXzoqzSZozl98-yM8p4nTdN9fPk4H6anYewKgo6E7P6RXZazWgjuOBn2Z9POMIYsdsMZH9RAXJK0PbYYkRnyW-MPWk92OC0itgSD92kIZDYA1E64h3GDXGGqGEga7VynliYondjjwMJ4NECGb2LkNAhkcmYMGBjeEQ7q3sEHVXA8CHhwzSkpPFuvfvjdr5Y3NyS6FENL7PnRg0BXj2cF9mPL5-_X3_LFzdf59dXi1zXnMUcWFUpLUypWJ0ibVuywoia1hQE70RZpFdFTUGB8Yq3mnamEVp3ApgCXfLqIpvvuZ1TKzl6XCu_kU6h3AWcX0rlI-oBpKgNr1mnaqYMM40SrOCdqQTTimqtysT6uGeNU7uGTqfWvRqOoMcZi71cujtJCyqaptkS3j0QvPs1QYhyjUHDMCgLbgqyFLQuGZ8VIknf_iNducnbNKuditei5AeqpUodoDUufay3UHk1Yw1PpmloUl3-R5VWB2vUyYwGU_yooNwXaO9C8GCemqSF3HpW7j0rk2flzrPyPhW9ORzPU8mjSau_bO_tjw |
| CitedBy_id | crossref_primary_10_2500_aap_2024_45_240013 crossref_primary_10_1016_j_biochi_2023_09_018 crossref_primary_10_3390_ijms242317120 crossref_primary_10_1183_23120541_00725_2023 crossref_primary_10_3389_fimmu_2023_1185727 crossref_primary_10_3389_fimmu_2023_1231047 crossref_primary_10_1016_S2213_2600_24_00176_0 crossref_primary_10_3389_fphar_2024_1396710 crossref_primary_10_3389_fimmu_2023_1239151 crossref_primary_10_3390_cancers15153954 crossref_primary_10_1183_16000617_0055_2024 crossref_primary_10_3389_fphar_2023_1208780 crossref_primary_10_1183_16000617_0234_2023 |
| Cites_doi | 10.1002/cpt.1053 10.3389/fphar.2018.00341 10.1177/1479972317709649 10.1016/j.biochi.2007.10.009 10.1124/pr.110.002733 10.4049/jimmunol.173.12.7277 10.1183/13993003.congress-2016.OA4539 10.1182/blood.V94.7.2487.419k07_2487_2496 10.1016/S2213-2600(20)30504-X 10.1172/JCI76009 10.1016/j.rmed.2012.12.009 10.1203/01.pdr.0000250043.90468.c2 10.1021/acs.jmedchem.6b01127 10.1155/2015/293053 10.1164/rccm.201605-1027OC 10.1016/j.celrep.2018.02.062 10.1172/JCI6092 10.1074/jbc.RA118.001922 10.1056/NEJMoa2021713 10.1016/S0140-6736(18)31767-7 10.1007/s40262-022-01147-w 10.1371/journal.pone.0272575 10.1172/JCI0213462 10.1016/j.chest.2017.03.056 |
| ContentType | Journal Article |
| Copyright | 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2023 |
| Copyright_xml | – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2023 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7U7 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PIMPY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12931-023-02444-z |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) Virology and AIDS Abstracts Toxicology Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1465-993X 1465-9921 |
| EndPage | 133 |
| ExternalDocumentID | oai_doaj_org_article_85f654da54af4f9a8406df384ca1cca2 A749699391 10_1186_s12931_023_02444_z 37198686 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United Kingdom |
| GeographicLocations_xml | – name: United Kingdom |
| GroupedDBID | --- -A0 0R~ 29P 2WC 3V. 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESX F5P FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RIG RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFPKN CITATION ABVAZ AFGXO AFNRJ 7QL 7U7 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c564t-e433ac8f2a45c56bb240f85151e86d8200f831f01e4636bc1df98ccd8e4aec263 |
| IEDL.DBID | RPM |
| ISSN | 1465-993X 1465-9921 |
| IngestDate | Tue Oct 22 15:09:37 EDT 2024 Tue Sep 17 21:31:26 EDT 2024 Fri Oct 25 10:16:26 EDT 2024 Sat Nov 09 13:10:11 EST 2024 Thu Feb 22 23:58:52 EST 2024 Tue Nov 12 22:16:51 EST 2024 Thu Sep 12 18:14:11 EDT 2024 Wed Oct 16 00:38:40 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Sputum biomarkers Dipeptidyl peptidase-1 inhibitor Cathepsin G Brensocatib Neutrophil elastase Neutrophil serine protease Non-cystic fibrosis bronchiectasis Proteinase 3 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c564t-e433ac8f2a45c56bb240f85151e86d8200f831f01e4636bc1df98ccd8e4aec263 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189992/ |
| PMID | 37198686 |
| PQID | 2815658268 |
| PQPubID | 42864 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_85f654da54af4f9a8406df384ca1cca2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10189992 proquest_miscellaneous_2815246708 proquest_journals_2815658268 gale_infotracmisc_A749699391 gale_infotracacademiconefile_A749699391 crossref_primary_10_1186_s12931_023_02444_z pubmed_primary_37198686 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-17 |
| PublicationDateYYYYMMDD | 2023-05-17 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Respiratory research |
| PublicationTitleAlternate | Respir Res |
| PublicationYear | 2023 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | CT Pham (2444_CR8) 2004; 173 JD Chalmers (2444_CR14) 2022; 61 S Seren (2444_CR10) 2018; 293 OE Sørensen (2444_CR16) 2014; 124 2444_CR15 PA Flume (2444_CR3) 2018; 392 S Janciauskiene (2444_CR18) 2018; 9 B Korkmaz (2444_CR9) 2010; 62 V Witko-Sarsat (2444_CR24) 1999; 94 JD Chalmers (2444_CR5) 2017; 195 R Palmér (2444_CR12) 2018; 104 B Korkmaz (2444_CR7) 2008; 90 JD Chalmers (2444_CR13) 2020; 383 PJ Cole (2444_CR2) 1986; 147 J Sedor (2444_CR25) 2007; 61 MS Twigg (2444_CR6) 2015; 2015 AM Adkison (2444_CR17) 2002; 109 DM Clancy (2444_CR23) 2018; 22 E Polverino (2444_CR19) 2017; 152 HR Keir (2444_CR1) 2021; 9 R Stockley (2444_CR20) 2013; 107 D Weycker (2444_CR4) 2017; 14 K Doyle (2444_CR11) 2016; 59 EJ Campbell (2444_CR22) 1999; 104 2444_CR21 |
| References_xml | – volume: 104 start-page: 1155 year: 2018 ident: 2444_CR12 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1053 contributor: fullname: R Palmér – volume: 9 start-page: 341 year: 2018 ident: 2444_CR18 publication-title: Front Pharmacol doi: 10.3389/fphar.2018.00341 contributor: fullname: S Janciauskiene – volume: 14 start-page: 377 year: 2017 ident: 2444_CR4 publication-title: Chron Respir Dis doi: 10.1177/1479972317709649 contributor: fullname: D Weycker – volume: 90 start-page: 227 issue: 2 year: 2008 ident: 2444_CR7 publication-title: Biochimie doi: 10.1016/j.biochi.2007.10.009 contributor: fullname: B Korkmaz – volume: 62 start-page: 726 year: 2010 ident: 2444_CR9 publication-title: Pharmacol Rev doi: 10.1124/pr.110.002733 contributor: fullname: B Korkmaz – volume: 173 start-page: 7277 year: 2004 ident: 2444_CR8 publication-title: J Immunol doi: 10.4049/jimmunol.173.12.7277 contributor: fullname: CT Pham – ident: 2444_CR21 doi: 10.1183/13993003.congress-2016.OA4539 – volume: 94 start-page: 2487 year: 1999 ident: 2444_CR24 publication-title: Blood doi: 10.1182/blood.V94.7.2487.419k07_2487_2496 contributor: fullname: V Witko-Sarsat – volume: 9 start-page: 873 year: 2021 ident: 2444_CR1 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30504-X contributor: fullname: HR Keir – volume: 124 start-page: 4539 year: 2014 ident: 2444_CR16 publication-title: J Clin Invest doi: 10.1172/JCI76009 contributor: fullname: OE Sørensen – volume: 107 start-page: 524 year: 2013 ident: 2444_CR20 publication-title: Respir Med doi: 10.1016/j.rmed.2012.12.009 contributor: fullname: R Stockley – volume: 61 start-page: 26 issue: 1 year: 2007 ident: 2444_CR25 publication-title: Pediatr Res doi: 10.1203/01.pdr.0000250043.90468.c2 contributor: fullname: J Sedor – volume: 59 start-page: 9457 year: 2016 ident: 2444_CR11 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b01127 contributor: fullname: K Doyle – volume: 2015 year: 2015 ident: 2444_CR6 publication-title: Mediators Inflamm doi: 10.1155/2015/293053 contributor: fullname: MS Twigg – volume: 195 start-page: 1384 year: 2017 ident: 2444_CR5 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201605-1027OC contributor: fullname: JD Chalmers – volume: 22 start-page: 2937 year: 2018 ident: 2444_CR23 publication-title: Cell Rep doi: 10.1016/j.celrep.2018.02.062 contributor: fullname: DM Clancy – volume: 104 start-page: 337 year: 1999 ident: 2444_CR22 publication-title: J Clin Invest doi: 10.1172/JCI6092 contributor: fullname: EJ Campbell – volume: 293 start-page: 12415 year: 2018 ident: 2444_CR10 publication-title: J Biol Chem doi: 10.1074/jbc.RA118.001922 contributor: fullname: S Seren – volume: 383 start-page: 2127 year: 2020 ident: 2444_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa2021713 contributor: fullname: JD Chalmers – volume: 147 start-page: 6 year: 1986 ident: 2444_CR2 publication-title: Eur J Respir Dis Suppl contributor: fullname: PJ Cole – volume: 392 start-page: 880 year: 2018 ident: 2444_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(18)31767-7 contributor: fullname: PA Flume – volume: 61 start-page: 1457 year: 2022 ident: 2444_CR14 publication-title: Clin Pharmacokinet doi: 10.1007/s40262-022-01147-w contributor: fullname: JD Chalmers – ident: 2444_CR15 doi: 10.1371/journal.pone.0272575 – volume: 109 start-page: 363 year: 2002 ident: 2444_CR17 publication-title: J Clin Invest doi: 10.1172/JCI0213462 contributor: fullname: AM Adkison – volume: 152 start-page: 249 year: 2017 ident: 2444_CR19 publication-title: Chest doi: 10.1016/j.chest.2017.03.056 contributor: fullname: E Polverino |
| SSID | ssj0017875 |
| Score | 2.502986 |
| Snippet | Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases (NSPs)... Abstract Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine... Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases... BackgroundBrensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases... BACKGROUNDBrensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine proteases... Abstract Background Brensocatib is an oral, selective, reversible inhibitor of dipeptidyl peptidase-1 (DPP-1), responsible for activating neutrophil serine... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 133 |
| SubjectTerms | Analysis Biological markers Blood Bone marrow Brensocatib Bronchiectasis Bronchiectasis - diagnosis Bronchiectasis - drug therapy Cathepsin G Clinical trials Correlation Cultures (Biology) Cystic Fibrosis Data analysis Dermatology Diagnosis Dipeptidyl peptidase-1 inhibitor Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - pharmacology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - therapeutic use Disease Drug therapy Elastase Enzyme inhibitors Exploratory behavior Health aspects Health services Humans Leukocyte Elastase Leukocytes (neutrophilic) Lung diseases Measurement Methods Myeloblastin Neutrophil elastase Neutrophil serine protease Neutrophils Non-cystic fibrosis bronchiectasis Patients Peptidases Periodontal disease Periodontal diseases Proteinase Proteinase 3 Reduction Review boards Safety Salix Serine Proteases - pharmacology Serine Proteases - therapeutic use Serine proteinase Sputum Sputum biomarkers Testing |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gL4k2gICMhcUBR48T22tzKo6qQChcqerNsx9YGLclqs3to_1T_IjNOstqIAxduSezYSb6xZyae-UzIW-m8iGXh81pZn3NtQ67r0uUMlIWOha4LjQnOF9_k-SX_eiWuDrb6wpiwgR54-HAnSkQpeG0Ft5FHbcEhkXWsFPeWQe_D7FvoyZka1w9ADMWUIqPkSY9aDdzmEtcsOef5zUwNJbb-v-fkA6U0D5g80EBnD8j90XSkp8MjPyR3QvuI3L0YF8cfk9vPzRpjVOrrFR0OQEPljDbtsnEpMoviX1cKTnALmAAkjm6QuTX0FMxAiikOuJME7SK1qxX9bX91G9qG3XbTrZfNivYpVZAmagdouoeW6cjL2k9Nd61fNjCJ2r7pP0Dz_W4FhZjEkvrAnwfff9K0V8gTcnn25cen83zcjyH3QvJtHnhVWa9iabmAK86BNRDBYhMsKFmDKQFnFYsFC8hC5jyro1be1ypwG3wpq6fkqO3a8JzQwGThgq34QmpunXY-LkrrQVTqEKy1GXk_wWPWA-2GSe6KkmYA0wCYJoFpbjLyERHc10TK7HQBBMmMgmT-JUgZeYf4GxzYALK3Y34CPDBSZJnTBdcSrDnNMnI8qwkD0s-LJwky44TQmxJZeQT4ciojb_bFeCcGubWh2w11SlBcBdR5Ngjc_pWqBdNKKpkRNRPF2TvPS9pmmejCkZMN3IDyxf_4Si_JvTINI5GzxTE52m524RWYZVv3Oo3AP7vHO-U priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELZgkRAXxJvAgoyExAFZGzu2a3NBy2O1Qlq4sKI3y3GcbVBJStMe2D_FX2TGSctGSNzS2HETzdue-YaQl7oMqhZ5YJXxgUnrI7OVKBkHY2Hr3Fa5xQLns8_69Fx-mqv5uOHWj2mVO52YFHXVBdwjPxIIa6LAGTZvVz8Zdo3C09WxhcZ1coOLXGNK12y-D7g4MKMaqosUAzs83xXNGH3Uo52DQFrgKaaUkl1ODFPC7_9XS18xU9MUyis26eQOuT06k_R4oP5dci2298jNs_G4_D75_aFZYdZK9WtJhwuwWYzTpl00ZcrVorgPSyEsboFKQKSSrhHLNfYUHEOKRQ_YW4J2NfXLJf3hv3dr2sbtZt2tFs2S9ql4kCawB1i6h5XpiNTa75bu2rBoQK36vunfwPL9dgmDWNaS_gO3E758o6l7yANyfvLx6_tTNnZoYEFpuWFRFoUPphZeKrhTluAf1ODDKR6NrsC5gF8Fr3MeEZesDLyqrQmhMlH6GIQuHpKDtmvjY0Ij13kZfSFn2kpf2jLUM-EDME8Vo_c-I6935HGrAYjDpQDGaDcQ0wExXSKmu8zIO6TgfiaCaKcb3frCjTLpjKq1kpVX0teyth5iXV3VhZHBc2BskZFXSH-Hog5EDn6sWIAXRtAsdzyTVgNfWZ6Rw8lMENEwHd5xkBtVRO_-MnRGXuyH8UlMe2tjtx3mCDBlOcx5NDDc_pOKGbdGG50RM2HFyTdPR9pmkQDEEaUNAgPx5P_v9ZTcEklAFOOzQ3KwWW_jM3DBNuXzJGd_AKhJNKA priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-G31lAiCD1Jtskk2EUTOj-MQTl9c3LeQpsltpbZruwve_VP-i07Sdr3i4dtuk822nd90ZpqZ3yD0TOSWe5rZtJDGpkwZl6qC5ikBY6F8popMhQLnk8_ieME-LflyD43tjoYb2F0a2oV-Uou2evnr59lbUPg3UeGleNUFmwVBMQ07koyx9PwKukoZROohlY_93VUAcPK-2oinYJeXYxHNpWtMDFXk8__3qX3BbE1TKi_YqKOb6MbgXOLDHg230J6rb6NrJ8P2-R30-0O5DlksxVmF-w9gw1KCy3pV5jF3C4f3shjC5BqkBkLLcRu4XV2HwVHEoQgi9JrAjcemqvAP871pce22m7ZZr8oKd7GYEEfyB1i6g5XxwNzajUs3tV2V8Jg1Xdm9huW7bQWDocwl_kd4vfDlG47dRO6ixdHHr--P06FjQ2q5YJvUwU03VnpqGIcjeQ7-ggefjhMnRQHOBnybEZ8RF3jKcksKr6S1hXTMOEvF7B7ar5vaPUDYEZHlzszYXChmcpVbP6fGApgK54wxCXoxikeve2IOHQMaKXQvTA3C1FGY-jxB74IEdzMDqXY80LSnetBRLbkXnBWGM-OZVwZiX1H4mWTWEAA6TdDzIH8dwAhCtmaoYIATDiRa-nDOlABcKZKgg8lMUFk7HR4RpEfEaxp4ezhEezJBT3fD4ZchDa52zbafQ8G0ZTDnfg-43SXN5kRJIUWC5ASKk2uejtTlKhKKB9Y2CBTow_-f1yN0nUYF4SmZH6D9Tbt1j8El2-RPop79AQvfOAI priority: 102 providerName: Scholars Portal |
| Title | Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37198686 https://www.proquest.com/docview/2815658268 https://search.proquest.com/docview/2815246708 https://pubmed.ncbi.nlm.nih.gov/PMC10189992 https://doaj.org/article/85f654da54af4f9a8406df384ca1cca2 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELbaIiEuiH8CZWUkJA4o3XXiODa3trSqkLZUiIreLNuxu0HZZLXZPdCX4hUZO8mqETcuURJPnEQz45mxZz4j9IFpk7lkZuKCKxNToWwsikTHBIyFcDNRzIQvcJ5fsotr-vUmu9lDbKiFCUn7RpdHdbU8qstFyK1cLc10yBObXs1PPcoUODbJdB_tg4QOMXq_dgAimHU1RVkMRGQoleFs2nrrBuFz4tcuKaXx3cgcBdT-f8fme8ZpnDh5zxKdP0GPexcSH3ef-hTt2foZejjvF8mfoz9fypXPVSl-V7g7AUsVE1zWi1KHDC3sZ18xBMM18AZYo_HaI7jaFoM7iH2pg99RAjcOq6rCS_WrWePabjfrZrUoK9yGkkEcIB6g6xZ6xj0-azt03dRmUcJgqtqy_Qzdt9sKGn0xS3iHn0T49hOHPUNeoOvzsx-nF3G_L0NsMkY3saVpqgx3iaIZ3NEavAIHnltGLGcFuBRwlRI3I9ajkWlDCie4MQW3VFmTsPQlOqib2r5G2BI201alNGeCKi20cXmiDIhMYa1SKkKfBvbIVQe_IUPYwpnsmCmBmTIwU95F6MRzcEfpobPDjWZ9K3sBkjxzLKOFyqhy1AkFES4rXMqpUQTEOYnQR89_6RUcmGxUX6cAH-yhsuRxTgUDr06QCB2OKEExzbh5kCDZDwytTDw6TwYxHY_Q-12zf9Inu9W22XY0CRiwGdC86gRu90tpTgRnnEWIj0Rx9M_jFtCiABs-aM2b_3_0LXqUBOXJYpIfooPNemvfgVO20RPQxJt8gh6cnF1efZ-EqQ04zimfBO38CwuVQGk |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,31732,33756,33757,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgk4AXxJ3AACMh8YCs5WK7Di9og00D1oLQJvpmOY5Ng0pSmvaB_Sn-Iuc4aVmExFsaO26ic7fP-Q4hL2RhhU9jy0plLOO5cSwv04IlYCxyH-dlnGOB83giT875h6mY9htubZ9WudGJQVGXjcU98v0UYU0EOMPqzeInw65ReLrat9C4SnYRqgqCr93Do8nnL9tzBGBH0dUXCQaWeLopm1Fyv0VLB6F0iueYnHN2MTBNAcH_Xz19yVANkygvWaXjW-Rm707Sg47-t8kVV98h18b9gfld8vtdtcC8lfLXnHYXYLVYQqt6VhUhW4viTiyFwLgGOgGZCrpENFfXUnANKZY9YHcJ2nhq5nP6w3xvlrR269WyWcyqOW1D-SANcA-wdAsr0x6rtd0s3dR2VoFiNW3Vvobl2_UcBrGwJfwHbih8-kpD_5B75Pz46OztCet7NDArJF8xx7PMWOVTwwXcKQrwEDx4cSJxSpbgXsCvLPFx4hCZrLBJ6XNlbakcN86mMrtPduqmdg8JdYmMC2cyPpI5N0VeWD9KjQX2KZ0zxkTk1YY8etFBcegQwiipO2JqIKYOxNQXETlECm5nIox2uNEsv-leKrUSXgpeGsGN5z43EO3K0meKW5MAa6cReYn01yjsQGRr-poFeGGEzdIHI55L4Ks8icjeYCYIqR0ObzhI90qi1X9ZOiLPt8P4JCa-1a5Zd3NSMGYxzHnQMdz2k7JRkiupZETUgBUH3zwcqatZgBBHnDYIDdJH_3-vZ-T6ydn4VJ--n3x8TG6kQVgES0Z7ZGe1XLsn4JCtiqe91P0BfjE49g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBUXxLuBAkZC4oDSjRPHa3MrLavy2NIDFb1ZtmOzQdlktdk90D_FX2TsJKtG3Lgl8diJNTOemXjmM0JvmDa5SxMTF1yZmAplY1GkOiZgLIRLRJEIX-A8P2dnl_TzVX7VZ1W2fVplbXR5VFfLo7pchNzK1dJMhjyxycX8xKNMgWOTTlaFm9xGd0BpEzZE6v0OAghi3lUW5TGQkqFghrNJ620cBNGp38GklMbXI6MUsPv_XaFvmKhx-uQNezS7j-71jiQ-7j74Abpl64dof95vlT9Cf07Llc9YKX5XuLsAexUTXNaLUoc8Lez_wWIIiWvgEDBI47XHcbUtBqcQ-4IHf64EbhxWVYWX6lezxrXdbtbNalFWuA2FgzgAPcDQLYyMe5TWdhi6qc2ihCVVtWX7HoZvtxU0-pKW8A7_K-HbDxxODnmMLmcfv5-cxf3pDLHJGd3ElmaZMtyliubwRGvwDRz4bzmxnBXgWMBdRlxCrMck04YUTnBjCm6psiZl2RO0Vze1PUDYEpZoqzI6ZYIqLbRx01QZEJzCWqVUhN4N7JGrDoRDhuCFM9kxUwIzZWCmvI7QB8_BHaUH0A4PmvVP2YuR5LljOS1UTpWjTiiIc1nhMk6NIiDUaYTeev5Lr-bAZKP6agX4YA-YJY-nVDDw7QSJ0OGIEtTTjJsHCZL98tDK1GP05BDZ8Qi93jX7nj7lrbbNtqNJwYwlQPO0E7jdlLIpEZxxFiE-EsXRnMctoEsBPHzQnWf_3_UV2r84ncmvn86_PEd306BHeUymh2hvs97aF-ClbfTLoI5_AdthQII |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dipeptidyl+peptidase-1+inhibition+with+brensocatib+reduces+the+activity+of+all+major+neutrophil+serine+proteases+in+patients+with+bronchiectasis%3A+results+from+the+WILLOW+trial&rft.jtitle=Respiratory+research&rft.au=Cipolla%2C+David&rft.au=Zhang%2C+Jimin&rft.au=Korkmaz%2C+Brice&rft.au=Chalmers%2C+James+D&rft.date=2023-05-17&rft.pub=BioMed+Central&rft.issn=1465-993X&rft.eissn=1465-9921&rft.volume=24&rft.spage=1&rft_id=info:doi/10.1186%2Fs12931-023-02444-z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-993X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-993X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-993X&client=summon |